At meeting held on 09 December 2017
The Board of Thyrocare Technologies has decided to defer a decision on payment of interim dividend pending assessment of requirement of funds to meet the capex requirements of the wholly-owned subsidiary, Nueclear Healthcare Limited, since the Company has already decided to give them loan to help them acquire costly equipment like Cyclotron, PET-CT Scan machines, etc., to set up additional scanning centres; to invest upto Rs. 20 crores in Equinox Labs Private Limited, Navi Mumbai-Rs. 10 crores in cash and by divestment of Water Testing Business to them for Rs. 10 crores, on slump sale basis, and to administer the ESOP schemes hereafter directly instead of through the Trust.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
